These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 624294)

  • 21. Antifibrinolytic activity during administration of epsilon-aminocaproic acid.
    Nibbelink DW
    Stroke; 1971; 2(6):555-8. PubMed ID: 5164583
    [No Abstract]   [Full Text] [Related]  

  • 22. Anti-fibrinolytic treatment in the pre-operative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm.
    Ameen AA; Illingworth R
    J Neurol Neurosurg Psychiatry; 1981 Mar; 44(3):220-6. PubMed ID: 7229645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation.
    Kang Y; Lewis JH; Navalgund A; Russell MW; Bontempo FA; Niren LS; Starzl TE
    Anesthesiology; 1987 Jun; 66(6):766-73. PubMed ID: 3296855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effectiveness of antifibrinolytic, edema-preventing and hypotensive agents in the prevention of recurrent bleeding from intracranial aneurysms].
    Bromowicz J; Bryniarska D; Koniar-Danilewicz H; Danilewicz B
    Neurol Neurochir Pol; 1979; 13(6):647-51. PubMed ID: 514441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Fibrinolytic activity of cerebrospinal fluid in subarachnoid hemorrhage (author's transl)].
    Imanaga H; Osugi T; Kagawa M; Kita-Mura K
    No Shinkei Geka; 1977 Jan; 5(1):51-8. PubMed ID: 557178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy.
    Leipzig TJ; Redelman K; Horner TG
    J Neurosurg; 1997 Feb; 86(2):220-5. PubMed ID: 9010423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Source of fibrin/fibrinogen degradation products in the CSF after subarachnoid hemorrhage.
    Vermeulen M; van Vliet HH; Lindsay KW; Hijdra A; van Gijn J
    J Neurosurg; 1985 Oct; 63(4):573-7. PubMed ID: 3897478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epsilon-aminocaproic acid (EACA).
    Griffin JD; Ellman L
    Semin Thromb Hemost; 1978; 5(1):27-40. PubMed ID: 568312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antifibrinolytics in aneurysmal subarachnoid haemorrhage. A retrospective comparison of two different forms of antifibrinolytic therapy.
    Spallone A
    Acta Neurochir (Wien); 1982; 63(1-4):245-50. PubMed ID: 6179402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antifibrinolytic therapy in aneurysmal subarachnoid hemorrhage increases the risk for deep venous thrombosis: A case-control study.
    Foreman PM; Chua M; Harrigan MR; Fisher WS; Tubbs RS; Shoja MM; Griessenauer CJ
    Clin Neurol Neurosurg; 2015 Dec; 139():66-9. PubMed ID: 26378393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prognostic value of cerebrospinal fluid fibrinolytic activity in meningeal hemorrhages as a result of aneurysm rupture].
    Rivierez M; Dagreou F; Guggiari M; Ankri A; Crespo B; Philippon J
    Neurochirurgie; 1983; 29(2):119-23. PubMed ID: 6888630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of cerebral vasospasm value of fibrinogen degradation products (FDP) in the cerebro-spinal fluid (CSF) for prediction of vasospasm following subarachnoid haemorrhage due to a ruptured aneurysm.
    Guggiari M; Dagreou F; Rivierez M; Mottet P; Gallais S; Philippon J; Viars P
    Acta Neurochir (Wien); 1984; 73(1-2):25-33. PubMed ID: 6496196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current status of intrathecal antifibrinolytic therapy with p-aminomethylbenzoic acid (PAMBA) in subarachnoid hemorrhages].
    Hindersin P; Endler S; Heidrich R; Lehmann W; Dietrich J
    Psychiatr Neurol Med Psychol (Leipz); 1985 Dec; 37(12):686-9. PubMed ID: 3879362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Fibrinolytic activity of cerebrospinal fluid as an indicator of the risk of repeated ruptures of arterial aneurysms].
    Kholodov SA; ShelkovskiÄ­ VN; Platonova TK
    Zh Vopr Neirokhir Im N N Burdenko; 1985; (4):18-22. PubMed ID: 4050242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antifibrinolytic therapy in ruptured intracranial aneurysm through repeated monitoring of fibrinolytic activity of blood.
    Watanabe H; Ito M; Chigasaki H; Ishii S
    Neurol Med Chir (Tokyo); 1976; 16(PT1):91-6. PubMed ID: 66644
    [No Abstract]   [Full Text] [Related]  

  • 36. Fibrinolytic activity in the CSF and blood following subarachnoid haemorrhage.
    Suzuki M; Kudo A; Otawara Y; Doi M; Kuroda K; Ogawa A
    Acta Neurochir (Wien); 1997; 139(12):1152-4. PubMed ID: 9479421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of epsilon-aminocaproic acid during peritoneal dialysis.
    Fish SS; Pancorbo S; Berkseth R
    J Neurosurg; 1981 Jun; 54(6):736-9. PubMed ID: 7241183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of early recurrence of spontaneous subarachnoid haemorrhage by epsilon-aminocaproic acid.
    Chowdhary UM; Carey PC; Hussein MM
    Lancet; 1979 Apr; 1(8119):741-3. PubMed ID: 85988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An examination of aneurysm rerupture rates with epsilon aminocaproic acid.
    Schuette AJ; Hui FK; Obuchowski NA; Walkup RR; Cawley CM; Barrow DL; Samuels OB
    Neurocrit Care; 2013 Aug; 19(1):48-55. PubMed ID: 22847395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental epsilon-aminocaproic acid (EACA) administration in the presence of subarachnoid blood.
    Ewald T; Mahaley S; Goodrich J; Wilkinson R; Silver D
    J Neurosurg; 1971 Dec; 35(6):657-63. PubMed ID: 5171110
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.